论文部分内容阅读
目的观察瑞舒伐他汀钙对脑梗死患者的血脂、超敏C-反应蛋白(hs-CRP)、动脉粥样硬化的影响。方法对68例脑梗死患者应用瑞舒伐他汀钙10mg/d口服,1周后观察hs-CRP的变化,治疗6个月后,观察用药前后血脂及颈动脉内膜中层厚度(IMT)的变化。结果经治疗1周后脑梗死患者的hs-CRP下降,6个月后患者血脂中总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)均有下降,高密度脂蛋白胆固醇(HDL-C)升高,IMT下降,且均有统计学差异(P<0.05或P<0.01)。结论瑞舒伐他汀钙可降低脑梗死患者的hs-CRP、LDL-C、TC、TG,升高HDL-C,并具有抗动脉粥样硬化的作用。
Objective To observe the effect of rosuvastatin calcium on serum lipids, hs-CRP and atherosclerosis in patients with cerebral infarction. Methods 68 patients with cerebral infarction were treated with rosuvastatin calcium 10 mg / d orally. The change of hs-CRP was observed one week later. The changes of blood lipid and carotid intima-media thickness (IMT) before and after treatment were observed 6 months after treatment. . Results The hs-CRP decreased in patients with cerebral infarction after 1 week of treatment. The levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) HDL-C and IMT decreased (P <0.05 or P <0.01). Conclusion Rosuvastatin calcium can reduce the hs-CRP, LDL-C, TC, TG and increase HDL-C in patients with cerebral infarction, and has the effect of anti-atherosclerosis.